Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant global health issue. Despite advancements in diagnostic methods and treatment strategies, challenges persist. This article aims to provide an updated approach to the diagnosis and management of enteric fever in clinical practice.
Diagnosis of enteric fever relies on clinical suspicion, backed by laboratory confirmation. Blood culture remains the gold standard, with sensitivity rates of 40-60%. However, its utility is limited by the need for specialized laboratory facilities and delayed results. Recent advancements include rapid diagnostic tests (RDTs) based on detection of specific antigens or antibodies. These offer the advantage of providing results within hours, but their sensitivity and specificity vary widely.
Treatment of enteric fever relies primarily on antibiotic therapy. However, the increasing incidence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains poses a significant challenge. Current guidelines recommend the use of third-generation cephalosporins or fluoroquinolones in regions with high rates of resistance. However, fluoroquinolones should be avoided in children due to potential side effects. In the case of XDR strains, newer antibiotics such as azithromycin and carbapenems may be considered.
Vaccination remains a crucial component of enteric fever prevention. Two vaccines are currently available: the oral live-attenuated Ty21a vaccine and the injectable Vi polysaccharide vaccine. Both have demonstrated efficacy, but neither provides complete protection. The development of new vaccines, particularly conjugate vaccines, offers promise for improved prevention strategies.
In conclusion, the diagnosis and management of enteric fever continue to evolve with advancements in diagnostic methods, the emergence of antibiotic resistance, and developments in vaccination. Clinicians must remain updated on these changes to ensure effective management and control of this significant global health issue.
1.
Melanoma Patient on Immunotherapy Develops Severe Dermatitis
2.
AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC
3.
FDA Approves Novel Targeted Therapy for Rare Blood Cancer
4.
Talquetamab Regimens Boost Survival in Multiple Myeloma
5.
A Possible Novel CAR-T Treatment for High-Risk R/R Follicular Lymphoma May Be Liso-Cel.
1.
Risk Assessment of Reduced Hematopoietic Reserve During Chronic Systemic Stress
2.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
3.
How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?
4.
Advanced Pathways in Oncology for Better Care
5.
Preventing Bleeding Complications During Anticoagulant Transitions
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
3.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
5.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation